Clinical Challenges: The Low-Down on HER2-Low

(MedPage Today) -- Reclassification of many HER2-negative breast cancers as HER2-low, combined with a new targeted treatment option for this subset, stands to benefit a wide swath of patients with metastatic or unresectable cases, but raises many...